Trial Profile
A 26-week treatment, multi-center, randomized, double-blind, double- dummy, placebo-controlled, parallel-group study to assess the efficacy, and safety of indacaterol (150 microg o.d.) in patients with chronic obstructive pulmonary disease, using salmeterol (50 microg b.i.d.) as an active control.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary) ; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms INLIGHT-2
- Sponsors Novartis
- 24 May 2017 Results (n=8445) of a pooled analysis from 11 Phase III/IIIb indacaterol studies assessing the efficacy and safety of once-daily indacaterol 150 and 300 ug in elderly patients with moderate to severe COPD, published in the Respiratory Medicine.
- 04 Jul 2012 Company added in the association field as reported by EudraCT.
- 23 Jun 2010 New source identified and integrated (Clinical Trials Registry - India).